SAB Biotherapeutics Inc (SABS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $266.66M
Last updated: Nov 17, 2026 at 11:05 AM ET
SAB Biotherapeutics Inc (SABS) Stock Forecast
Analysts expect SAB Biotherapeutics (SABS) to earn -$1.13 per share in the fiscal year ending Dec 31, 2026. Of 11 analysts, 11 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 1.91, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 9.1% |
| Buy | 10 | 90.9% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$1.13
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.94
- EPS consensus
- Next report
- Mar 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.13 | -$1.16 to -$1.06 | 3 |
| Dec 31, 2027 | -$0.94 | -$1.20 to -$0.60 | 5 |
Quarterly Estimates
The EPS consensus is -$0.25 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.25 | -$0.30 to -$0.11 | 13 |
| Mar 31, 2027 | -$0.25 | -$0.32 to -$0.21 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.16.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.13 | -$1.16 | -$1.16 | -$1.16 | -$1.16 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.94 | -$0.95 | -$0.95 | -$0.95 | -$0.95 | N/A |
| Quarter ending Mar 31, 2027 | -$0.25 | -$0.21 | -$0.21 | -$0.21 | -$0.21 | N/A |
Frequently Asked Questions About SABS
What is the SABS stock forecast?
Consensus analyst estimates put SAB Biotherapeutics's EPS at -$1.13 for the fiscal year ending Dec 31, 2026. The consensus rating from 11 analysts is Buy.
How do analysts rate SABS stock?
Of 11 analysts covering SAB Biotherapeutics, 1 rates it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from SABS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.13, with estimates from -$1.16 to -$1.06 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.94, with estimates from -$1.20 to -$0.60 from 5 analysts.
How many analysts cover SABS?
11 analysts rate SAB Biotherapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
SABS pages: Overview, Earnings, Forecast, Financials, Competitors